收费全文 | 1723篇 |
免费 | 70篇 |
国内免费 | 35篇 |
财政金融 | 124篇 |
工业经济 | 54篇 |
计划管理 | 332篇 |
经济学 | 213篇 |
综合类 | 237篇 |
运输经济 | 25篇 |
旅游经济 | 139篇 |
贸易经济 | 351篇 |
农业经济 | 187篇 |
经济概况 | 166篇 |
2024年 | 9篇 |
2023年 | 81篇 |
2022年 | 39篇 |
2021年 | 84篇 |
2020年 | 123篇 |
2019年 | 71篇 |
2018年 | 58篇 |
2017年 | 68篇 |
2016年 | 56篇 |
2015年 | 47篇 |
2014年 | 131篇 |
2013年 | 154篇 |
2012年 | 160篇 |
2011年 | 156篇 |
2010年 | 116篇 |
2009年 | 94篇 |
2008年 | 113篇 |
2007年 | 74篇 |
2006年 | 70篇 |
2005年 | 33篇 |
2004年 | 25篇 |
2003年 | 22篇 |
2002年 | 13篇 |
2001年 | 8篇 |
2000年 | 5篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1995年 | 2篇 |
1988年 | 1篇 |
1980年 | 1篇 |
Methods: Identified literature was screened according to pre-specified criteria to access legibility for inclusion. Each included piece of literature was systematically compared against the recommendations proposed by the relevant Chinese guidelines.
Results: After culling, 259 studies were included in the comparative analysis. When compared to a previous study evaluating the quality of similar literature published between 1997–2007, the results showed improvements in certain technical aspects over the years. Particularly, an improvement was observed in more diverse evaluation methods being used, increased use of cost-utility analysis (2.43% in 2012–2014 vs 0.26% in 1997–2007) and use of discounting (45% in 2012–2014 vs 4.35% in 1997– 2007). In addition, a small number of studies were starting to apply modeling.
Conclusion: The quality of economic evaluation literature has improved in recent years, with more researchers realizing the importance and necessity of using discounting, sensitivity analysis, and modeling when conducting economic evaluation. This study also highlights certain important areas needing further attention when conducting economic evaluations in China. These include the ICER threshold of economic analysis, more detailed guidance in performing sensitivity analysis and modeling, as well as transferability of cost data across different regions. Overall, the results would support the positive contribution of the Chinese Economic Guideline in promoting economic evaluations in China. 相似文献
Methods: A comparative review of key features of the pharmacoeconomic guidelines in SA was undertaken using the Comparative Table of Pharmacoeconomic Guidelines developed by the International Society of Pharmacoeconomics and Outcomes Research, and published country-level pharmacoeconomics guidelines. A random sample of guidelines in high- and middle-income countries were analyzed if data on all key features were available. Key features of the pharmacoeconomic guidelines in SA were compared with those in other countries, and divergent features were identified and elaborated.
Results: Five upper middle-income countries (Brazil, Colombia, Cuba, Malaysia, and Mexico), one lower middle-income country (Egypt), and six high-income countries (Germany, Ireland, Norway, Portugal, Taiwan, and the Netherlands) were analyzed. The pharmacoeconomic guidelines in SA differ in important areas when compared with other countries. In SA, the study perspective and costs are limited to private health-insurance companies, complex modelling is discouraged and models require pre-approval, equity issues are not explicitly stated, a budget impact analysis is not required, and pharmacoeconomic submissions are voluntary.
Conclusions: Future updates to the pharmacoeconomic guidelines in SA may include a societal perspective with limitations, incentivize complex and transparent models, and integrate equity issues. The pharmacoeconomic guidelines could be improved by addressing conflicting objectives with policies on National Health Insurance, incentivize private health insurance companies to disclose reimbursement data, and require the inclusion of a budget impact analysis in all pharmacoeconomic submissions. Further research is also needed on the impact of mandatory pharmacoeconomic submissions in middle-income countries. 相似文献